Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
Company fined $300K after worker injured in a chilled meat storage area
The company was fined in the District Court of NSW as a result of a prosecution by SafeWork NSW.
2025 Australian International Olive Awards held in Adelaide
Winners of the Australian Olive Association's annual international olive product awards were...
FSANZ's annual report defined by safety & scientific progress
During 2024–25, Food Standards Australia New Zealand supported 87 food recalls, 10 food...
